American regulators have cleared an AI tool that estimates whether a woman's breast cancer is likely to come back, moving a kind of software long confined to research closer to the clinic. SimBioSys said the Food and Drug Administration granted 510(k) clearance to TumorSight Risk, a cloud-based system that reads a standard breast MRI and returns a recurrence risk score.
The tool is meant as a prognostic aid, not a verdict. It covers adult women with hormone receptor-positive, HER2-negative breast cancer at stages I through IIIA, the most common form of the disease, including both node-negative and limited node-positive cases. From a dynamic contrast-enhanced MRI, together with a patient's age, tumour stage, nodal status and grade, it produces a score from 0 to 100 and sorts each case into low, intermediate or high risk of recurrence over five and ten years. Clinicians are expected to weigh that alongside the usual clinical and pathological factors rather than treat it as the final word.
Built from scans already taken
What sets the system apart is what it does not require. SimBioSys says TumorSight Risk works from imaging collected during routine care, with no extra procedure, no tissue sent to a lab, and no specialised hardware. Because it reads an MRI rather than a biopsy sample, a risk estimate can be available before surgery, early enough to shape the conversation about treatment. The company says the software runs on Nvidia hardware and builds on its earlier cleared platform, TumorSight Viz.
The clearance rests on a blinded, multi-institutional validation study of 2,129 patients drawn from Mayo Clinic, Emory University, Stanford Medicine and Mercy. That is a substantial dataset for this kind of tool, though a retrospective study is not the same as proving the software changes outcomes once oncologists start acting on its scores.
A quieter kind of medical AI
Recurrence scoring has traditionally leaned on genomic tests that require tumour tissue and a wait for lab results. An imaging-based estimate offers a faster, cheaper route, assuming it holds up in practice. It also sits apart from the louder claims that tend to dominate medical-AI coverage. We recently examined the gap between benchmark results and real diagnosis, and a clearance like this is the less glamorous version of the same story: a narrow tool, a defined population, a specific decision. It is also part of a broader push to have models read the body's own signals, from scans to the hidden history of a single cell.
Commentarii · 0